P.D. :Aqui abajo tenemos los Datos y Plazos del estudio de Fase II del Zentylor en Paralisis Supranuclear Progresiva a fecha 27 de Julio del 2010 ... Habiendo obtenido los Status de Orphan drug ( Nov 2009 ) y Fast Track ( Sept 2010 ) y viendo que la Fase II podría estar completada a mediados del 2011 ... ahi estamos a menos de 7 meses para empezar a tener ya resultados del ensayo .****************************************
http://clinicaltrials.gov/archive/NCT01049399/2010_07_27
View of NCT01049399 on 2010_07_27
ClinicalTrials Identifier: NCT01049399
Updated: 2010_07_27
Descriptive Information
Brief title Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Official title A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Brief summary
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
Detailed description
Phase Phase 2
Study type Interventional
Recruitment Information
Status Recruiting
Start date 2009-12
Last follow-up date 2011-06 (Anticipated)
Primary completion date 2011-04 (Anticipated)
.
